Skip to Content
You are currently on the new version of our website. Access the old version .
  • Review
  • Open Access

9 March 2026

15 Pages

Targeted Medical Therapy for Vestibular Schwannomas: Evidence, Limits, and Future Directions—A Scoping Review

,
,
,
,
,
,
and
1
Otolaryngology-Head and Neck Surgery Department, University of Verona, 37129 Verona, Italy
2
Audiology, Primary Care Ausl Modena, 41121 Modena, Italy
*
Authors to whom correspondence should be addressed.

Abstract

Background: Vestibular schwannomas (VSs) are benign tumors that can cause significant morbidity, particularly in neurofibromatosis 2 (NF2) patients, in whom conventional treatments have important limitations. Merlin is a tumor suppressor protein encoded by the Neurofibromin 2 (NF2) gene, and the loss of its function leads to the activation of multiple signaling pathways, providing a rationale for targeted pharmacological therapies. Agents such as bevacizumab and other receptor tyrosine kinase inhibitors (TKIs) have shown variable efficacy but remain limited by toxicity and inconsistent responses. This review aims to evaluate the efficacy and safety of targeted therapies for VSs. Methods: This study was conducted according to PRISMA 2020 guidelines, using a PICO-based search of PubMed, EMBASE, and Scopus to identify studies on pharmacological therapies for VSs published between 2000 and 2025. Eligible human studies included clinical trials and observational studies reporting efficacy, safety, neuroimaging and audiological outcomes. Results: In total, 23 studies were analyzed, predominantly involving NF2-associated VSs. Treatment with bevacizumab was the most frequently investigated medical therapy and yielded the most consistent tumor control along with occasional hearing improvement, albeit with frequent but mostly manageable adverse events. Other targeted agents, including everolimus and TKIs, demonstrated limited or variable efficacy with acceptable toxicity profiles. Conclusions: VSs, particularly in NF2 patients, can cause significant morbidity and are often poorly managed by surgery or radiotherapy. Consequently, targeted medical therapies, especially anti-angiogenic agents, have emerged as valuable alternatives. Bevacizumab shows the most consistent benefits in tumor control, hearing stabilization, and quality of life, despite heterogeneous responses and notable toxicity. Evidence suggests that treatment discontinuation may lead to rapid tumor rebound, highlighting the need for long-term or maintenance strategies and careful monitoring. Future studies are needed to evaluate medical therapy integration with conventional treatments.

1. Introduction

Vestibular schwannomas (VSs) are benign, typically slow-growing neoplasms that originate from the Schwann cell sheath of the vestibulocochlear nerve [1,2]. These neoplasms represent the most common benign tumor at the cerebellopontine angle and manifest with symptoms such as hearing loss, tinnitus, vertigo and dizziness. While the majority of VSs occur sporadically, often presenting as unilateral tumors in the fifth or sixth decade of life, approximately 4% to 10% of cases are associated with neurofibromatosis type 2 (NF2-related schwannomatosis) [1,3]. NF2 is an autosomal dominant tumor predisposition syndrome caused by inactivating mutations in the NF2 tumor suppressor gene on chromosome 22q12 [4]. The NF2 gene codes for the tumor suppressor Merlin, whose loss of function is the main pathogenic factor in VS pathogenesis.
NF2-associated VSs are typically bilateral, present earlier in life, and exhibit more aggressive growth dynamics [5,6]. These tumors lead to significant morbidity, including progressive sensorineural hearing loss, tinnitus, vertigo, and potentially life-threatening brainstem compression [2,7].
The current standard management for these diseases includes conservative observation (“wait and scan”), microsurgical resection, and stereotactic radiotherapy [4]. However, these modalities have significant limitations, particularly in the NF2 population, among whom surgical resection is associated with a high risk of facial nerve impairment and permanent hearing loss [3,5].
The search for beneficial alternatives has driven recent efforts toward the development of new therapeutic agents based on the principles of targeted therapy. The biological rationale for exploring pharmacological targeted therapies lies mainly in the functional loss of Merlin [8], which acts as a negative regulator of multiple mitogenic signaling pathways. The absence of this regulator leads to the abnormal activation of various receptor tyrosine kinases (RTKs) and downstream cascades, including the PI3K/AKT pathway, the Ras/RAF/MEK/ERK pathway, and the mTORC1 pathway [1,4,9]. Overexpression and activation of the ErbB family, specifically EGFR, ErbB2 and ErbB3, have been consistently observed in VSs, providing concrete molecular targets for therapeutic intervention [1,4]. Other pathways involving vascular endothelial growth factor (VEGF), platelet-derived growth factor receptor (PDGFR), c-Met, and Src have been identified as clinical or preclinical drivers of tumor growth [8,10,11].
Inactivation of NF2 represents the central pathogenic event in both sporadic and NF2-associated VSs, with different underlying mechanisms. In particular, NF2-associated VSs arise from germline or mosaic NF2 mutations, conferring a systemic predisposition to the development of multiple schwannomas and other central nervous system tumors [12].
To date, bevacizumab, a humanized monoclonal antibody targeting VEGF-A, has demonstrated the most significant clinical benefit, such as tumor shrinkage and hearing improvement [6]. Bevacizumab exerts its effect by selectively binding VEGF-A, thereby preventing its interaction with endothelial VEGF receptors and inhibiting tumor-associated angiogenesis [13,14]. VEGF blockade not only limits neovascularization but also reduces vascular hyperpermeability [12].
Beyond anti-angiogenic therapy, several agents targeting signaling pathways deregulated by Merlin loss have been evaluated. Small-molecule tyrosine kinase inhibitors (TKIs) such as lapatinib, icotinib, and erlotinib act by reversibly inhibiting EGFR and/or ErbB2, thereby suppressing downstream signaling cascades including ERK1/2 and AKT [9].
Axitinib is a highly potent oral inhibitor of VEGFR-1, -2, and -3, with additional activity against PDGFRα/β and c-KIT [10]. Given that Schwann cells express PDGF receptors that directly promote their proliferation, axitinib offers a dual mechanism of action by both starving the tumor through VEGFR inhibition and directly suppressing Schwann cell growth via PDGFR blockade [10].
Pazopanib exhibits a similar inhibitory profile, targeting VEGFR, PDGFR, and c-KIT to impair angiogenesis and tumor cell survival [15].
Another therapeutic target in NF2 is represented by the mTOR signaling axis. In this case, Merlin loss leads to constitutive mTORC1 hyperactivation, which acts as a central metabolic switch coordinating protein synthesis and cell cycle progression in response to nutrient and energy availability [9,16]. Everolimus, an oral rapamycin derivative and selective mTORC1 inhibitor, reduces cellular proliferation and may indirectly suppress VEGF production, thereby exerting additional anti-angiogenic effects [9].
Despite these developments, there is a lack of prospective data on maintenance therapy and the optimal dosing regimens needed to balance efficacy with toxicity over time [13,16]. The aim of this review is to synthesize clinical outcomes and to identify the most promising molecular targets and current clinical limitations.

2. Materials and Methods

The literature review was conducted in accordance with the criteria outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 [13]. The review question was formulated using the PICO framework. The population consisted of patients with acoustic neuroma/vestibular schwannoma, irrespective of age, sex, or tumor size. Interventions included systemic or targeted pharmacological therapies, such as anti-VEGF agents (e.g., bevacizumab), mTOR inhibitors (e.g., everolimus, sirolimus), antiangiogenic agents, molecular targeted therapies, and other emerging pharmacological approaches. Comparisons involved no treatment, placebo, surgical resection, radiotherapy, or other conservative treatment modalities. Outcomes assessed included treatment efficacy and safety, such as tumor control through neuroimaging or volumetric regression, hearing preservation, reduction in vestibular symptoms, treatment-related toxicity and adverse events, progression-free survival (PFS), and overall survival (OS).
The literature search was performed using PubMed/MEDLINE, EMBASE, and Scopus. Database-specific search strategies were developed using combinations of controlled terms (MeSH/Emtree) and text words related to vestibular schwannoma, pharmacological therapies (including targeted and antiangiogenic agents), and treatment outcomes. Searches were limited to English-language articles published between 2000 and 2025 in order to ensure the inclusion of literature reflecting contemporary diagnostic criteria and clinical practices, thereby enhancing the relevance and applicability of the findings to current clinical settings. Full electronic search strategies are available in the Supplementary Materials.
Following the initial literature search, the full texts of potentially eligible studies were retrieved and screened for final inclusion. All records identified during the initial search were independently reviewed by three authors (CM, MG, and MS). Any discrepancies were resolved through discussion or, when necessary, by consultation with a senior reviewer (AEA). A second screening phase involved full-text assessment conducted independently by four reviewers (AEA, CM, MG, and MS). Titles and abstracts were screened to identify relevant studies.
Studies were included if they met all the following criteria:
-
Publication in the English language;
-
Available as full-text articles;
-
Studies conducted using human subjects;
-
Clinical trials, case series including ≥5 patients, systematic reviews, and prospective or retrospective studies;
-
A primary focus on the pharmacological treatment of vestibular schwannoma;
-
Reported outcomes related to efficacy, safety, or tumor control, including MRI and/or audiological results.
The exclusion criteria were as follows:
-
Single case reports;
-
Non-English publications;
-
Preclinical studies, including animal or in vitro investigations;
-
Studies addressing schwannomas in anatomical locations other than the vestibular nerve or studies on neurofibromatosis without a clear distinction of vestibular schwannoma.
In total, 702 records were initially identified through database searches. After removing duplicates, 486 records remained for assessment. Of these, 69 full-text articles were selected for further evaluation. Full texts were then assessed according to predefined inclusion and exclusion criteria. Discrepancies in the selection process were resolved, when necessary, by consulting a senior reviewer (DM, LS). Ultimately, 22 articles were included. For each study, key information was extracted, including authorship, country of origin, year of publication, sample size, drug, dosage and schedule, adverse events, and main findings.

3. Results

A summary of the 22 selected articles is presented in Table 1. Seven studies were prospective, eleven were retrospective, and four were clinical trials, for a total of 685 cases.
Table 1. Summary of the analyzed articles. Targeted agents evaluated in the included studies: bevacizumab (anti-VEGF monoclonal antibody), everolimus (mTOR inhibitor), lapatinib (dual EGFR/HER2 tyrosine kinase inhibitor), axitinib (VEGFR tyrosine kinase inhibitor), pazopanib (multitarget VEGFR tyrosine kinase inhibitor), erlotinib and icotinib (EGFR tyrosine kinase inhibitors), and aspirin (nonsteroidal anti-inflammatory drug).
All studies primarily included NF2-associated cases, with the exception of one study [24], in which NF2 was an explicit exclusion criterion and the population consisted exclusively of patients with sporadic VSs. This study, in which all 361 patients were treated with aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), confirmed that aspirin and other NSAIDs do not exert a significant effect on tumor growth. For reasons of methodological transparency and completeness, this study was included in the selection process and reported in the summary table, but it was ultimately excluded from the quantitative and qualitative analysis, as it was not comparable with the remaining cohorts. The final population analysis consisted of 324 NF2 cases. In nine of these studies, only adult patients were included; in one study, only pediatric patients were considered; and in the remaining 12 studies, mixed populations were used.
Based on information reported on previous tumor treatments, 110 subjects had undergone prior surgery, while 23 had received prior radiotherapy. Most studies reported pre-treatment imaging and audiological data, except for one [14], which lacked neuroimaging data. Four studies [6,24,28,30] included a control group.
Bevacizumab was used in 68.2% of the studies (15/22), representing around 76% of the total cases, while everolimus was used in 3 of 22 studies [15,16,17]. Among the remaining studies, two studies [3,9] involved lapatinib and icotinib, one used axitinib [10], and one used erlotinib [29].

3.1. Bevacizumab

Detailed schedules of bevacizumab doses are provided in Table 2.
Table 2. Bevacizumab administration details.
The median follow-up was 25.2 months. Concerning imaging outcomes, assessed by MRI, a 20% change in tumor volume was considered clinically significant, an increase of >20% as disease progression, a decrease of >20% as disease regression, and a decrease of <20% as stable disease [32].
The detailed neuroimaging outcomes from the 15 studies using bevacizumab, encompassing a total of 242 treated patients, are as follows: stable in 141 (58.2%), progression in 17 (7.2%), and progression in 84 (34.6%). Regarding audiological outcomes, data were heterogeneous, with results sometimes reported per patient and other times per ear, often without precise numerosity. Overall, 8 of 15 studies described a deterioration of hearing among a portion of the population, most reported patients with stable hearing, and five studies reported a subset of patients showing hearing improvement. Functional hearing outcomes were evaluated using PTA (Pure Tone Average) and WRS (Word Recognition Score).
Regarding adverse events associated with bevacizumab (Table 3), the studies overall indicate a high frequency of events, predominantly mild to moderate (Grade 1–2), whereas severe events (Grade ≥ 3) are less common but not negligible. In most cases, a permanent discontinuation of therapy was not necessary. Grade 3 events were reported in a minority of patients, while Grade 4–5 events were rare, except for a single death due to cerebral hemorrhage [26]. The Common Terminology Criteria for Adverse Events (CTCAE), developed by the National Cancer Institute (NCI), was used to discriminate adverse effects; it classifies the severity of adverse events (AEs) from Grade 1 to 5 [33].
Table 3. Adverse events associated with bevacizumab across studies.
Figure 1 presents the number of studies reporting each specific complication, stratified by the type of adverse event.
Figure 1. Number of studies reporting each category of adverse events. Each category was counted only once per study, regardless of the number or severity of reported adverse events.

3.2. Everolimus

Three studies investigated the use of everolimus at a dose of 10 mg/kg/day orally, reducible to 5 mg/kg/day in pediatric patients or in cases of toxicity. In none of these studies was efficacy observed regarding tumor volume reduction or improvement in audiological outcomes. Tumor regrowth and deterioration of hearing function were reported upon drug discontinuation, suggesting the drug’s potential role in preserving hearing and possibly delaying the need for surgery or radiotherapy [16]. Overall, the toxicity profile was predominantly mild to moderate (Grade 1–2). The most frequently reported side effects included mucositis or oral ulcers, fatigue, headache, skin manifestations such as rash or acne, and metabolic disturbances, including hypercholesterolemia and hypertriglyceridemia. Severe adverse events (Grade ≥ 3) were sporadic, including pneumonia, basal cell carcinoma, and pulmonary toxicity, along with a single Grade 4 event of hypertriglyceridemia. No Grade 5 events were observed. Treatment modifications were limited, and permanent discontinuation was necessary in only one patient due to pulmonary toxicity [17]. Overall everolimus appears ineffective at inducing tumor shrinkage. However, the available studies suggest that the drug may contribute to disease stabilization in some patients [9,15], as everolimus appears more cytostatic than cytotoxic [15,16].

3.3. Tyrosine Kinase Inhibitors (TKI)

For TKI use, the results are as follows: Plotkin [29] administered erlotinib with a 36-month follow-up and predominantly mild adverse events; no significant clinical responses were observed. Karajannis [9] administered lapatinib to 17 patients, and the 14-month follow-up showed promising but preliminary results, with volumetric tumor reduction in approximately 24% of cases and hearing improvements in 31%. Zhao [3] administered icotinib to 11 patients; the drug was well tolerated and produced positive outcomes. Lastly, Garcia [10] administered axitinib. The treatment was well tolerated but yielded only moderate responses regarding tumor volume and hearing function.

4. Discussion

Recent insights into the molecular and cellular mechanisms underlying tumor pathogenesis have enabled the development of biologically targeted therapies for tumors that are otherwise difficult to treat. In particular, recurrent schwannomas following irradiation or previous surgery currently lack effective chemotherapeutic options. Moreover, in patients with NF2, bilateral VSs frequently result in severe/profound hearing loss. Medical treatment is also indicated for patients with progressive tumors in their only hearing ear or in tumor progression when standard options have been exhausted [15,21,34,35].
Pharmacological therapy offers a systemic approach, which is crucial in NF2 patients who often present not only with bilateral VSs but also with meningiomas and ependymomas, which are all potentially responsive to systemic therapy [14]. On the other hand, existing studies are often characterized by small sample sizes and heterogeneous patient populations, complicating the ability to draw definitive clinical conclusions [3,16].
This review confirmed that bevacizumab is currently the most effective pharmacological therapy for the treatment of progressive VSs in NF2 [10,21,28], although additional studies are required to further clarify the drug’s effects [36]. It also remains critical to identify which patient populations may benefit most from this treatment and the optimal overall duration of therapy. During a maintenance regimen, prolonged treatment interruptions (≥3 months) are associated with significant tumor regrowth. Additionally, some patients who had previously achieved a partial response failed to regain the same degree of tumor reduction [28]. Overall, the sources indicate that discontinuing therapy after achieving stability or a positive response is not advisable without extremely close follow-up, suggesting the need for an intensive clinical surveillance lasting at least 6 months following any interruption of anti-VEGF therapy [15,20]. “Rebound growth” is defined as an increase in VS volume exceeding 20% relative to the pre-discontinuation tumor volume, occurring within six months after stopping bevacizumab [21]. Volumetric data underscore that tumor growth following bevacizumab cessation can be extremely rapid and substantial. This phenomenon can be interpreted as a direct consequence of the predominantly suppressive nature of currently available targeted therapies [21]. These agents act by transiently “freezing” or normalizing dysregulated biological processes. Another hypothesis for bevacizumab is attributed to the persistence of a residual vascular scaffold within the tumor. A dormant vascular framework composed of basement membrane structures and pericytes could remain intact during treatment and upon drug withdrawal, enabling rapid vessel reperfusion or neoangiogenic regrowth along these pre-existing vascular “tracks” [2].
During prolonged therapy, increases in circulating hypoxia-induced cytokines and alternative pro-angiogenic factors, such as placental growth factor and hepatocyte growth factor, have also been observed. This accumulation of pro-tumorigenic signals may further amplify tumor regrowth immediately after bevacizumab discontinuation, acting as a molecular “accelerator” once the VEGF blockade is lifted [6].
A similar “released brake” effect was proposed for therapies targeting mTORC1 or EGFR signaling, which are predominantly cytostatic [18]. In the context of persistent Merlin deficiency, these agents impose an artificial block on constitutively active growth pathways. Following treatment cessation, tumor cells that had been arrested in the G1 phase re-enter the cell cycle synchronously, resulting in rapid tumor regrowth [3,16].
A significant emerging factor is the different response observed between adults and children. Children tend to have higher pre-treatment tumor growth rates [6,33] and exhibit significantly lower rates of tumor shrinkage when compared with adults, although children may still derive meaningful benefits in disease stabilization and quality of life.
In the pediatric population, the primary therapeutic goal is therefore not always complete tumor eradication, but rather the long-term preservation of functional hearing and facial nerve integrity [10,35]. The resistance to tumor shrinkage observed in this population can be explained by a convergence of genetic, biological, and microenvironmental factors. Pediatric VSs are more frequently associated with severe clinical phenotypes and are characterized by a higher prevalence of truncating NF2 mutations that result in complete loss of merlin function and drive a markedly more aggressive proliferative program (as reflected by significantly elevated cellular density and proliferation indices). Consequently, these tumors are intrinsically less susceptible to pharmacologically induced volumetric regression [6,12].
Pediatric tumors exhibit a distinct angiogenic profile. Biomarker analyses indicate that, during treatment with bevacizumab, children tend to maintain higher circulating levels of free VEGF [6]. This factor limits the duration and effectiveness of vascular normalization, favoring stabilization rather than true tumor shrinkage. In the context of high baseline proliferative activity, these therapies function mainly as a “brake” on tumor growth rather than inducing meaningful reduction in already established tumor masses [6,35]. Finally, therapeutic response in pediatric patients may be further influenced by prior surgical intervention. Partial resections, commonly performed to decompress the internal auditory canal or preserve neurological function, can alter the tumor microenvironment by inducing inflammatory responses and releasing growth factors such as VEGF and matrix metalloproteinases. These post-surgical changes may stimulate residual tumor tissue and contribute to the greater heterogeneity and reduced predictability of medical treatment outcomes in the pediatric setting [6].
Studies indicate that hearing response is inversely associated with baseline levels of hepatocyte growth factor (HGF), suggesting the possible role of HGF in resistance mechanisms or as a marker of a tumor microenvironment more susceptible to bevacizumab-induced vascular normalization. In contrast, the neuroimaging response is associated with elevated baseline levels of VEGF-D and SDF1α, biomarkers reflecting increased vascular permeability and a strong dependence of the tumor on angiogenic signaling. Overall, these findings support the hypothesis that bevacizumab acts through two distinct mechanisms: a reduction in the intratumoral edema and a reduction in the hyperpermeable vascular component. However, studies employing higher dosing regimens have not consistently confirmed these correlations, suggesting that dose intensification may alter these underlying biological equilibria [14,28].
One notable finding from the literature is the discrepancy between clinical outcomes (as measured by physicians) and patient-reported well-being. Several studies have documented significant improvements in NF2-specific quality of life scores (NFTI-QOL) within 3–6 months of treatment, often independent of neuroimaging or objective hearing responses. Patients report feeling better because therapy alleviates symptoms not easily captured by imaging, such as aural pressure, balance disturbances, and pain [7,29]. Bevacizumab treatment is also associated with reduced tinnitus-related distress in approximately 60% of patients. Studies using instruments such as the Tinnitus Reaction Questionnaire (TRQ) have shown significant decreases in the psychological burden of tinnitus, contributing substantially to the overall perception of benefit [7,21].
Numerous in vitro preclinical studies have investigated innovative molecularly targeted therapeutic strategies for VSs, providing relevant insights for future clinical applications. In particular, Lu et al. identified cellular senescence as a therapeutically exploitable vulnerability in NF2-associated VSs, demonstrating that genotoxic agents induce a stable senescent phenotype mediated by the DNA damage–p21 axis and accompanied by activation of the senescence-associated secretory phenotype (SASP) [37]. Selective elimination of senescent cells using the senolytic agent navitoclax effectively induced apoptosis, supporting a sequential “one–two punch” therapeutic strategy [37]. Other studies have highlighted the efficacy of combined targeted approaches, such as the simultaneous inhibition of BET proteins and FAK, which produced synergistic antitumor effects in NF2-deficient VSs models [38]. In parallel, NF-κB signaling has emerged as a key regulator of tumor proliferation and a promising pharmacological target. Several TKIs, including nilotinib, ponatinib, cabozantinib, and saracatinib, have demonstrated marked antiproliferative effects through the inhibition of PDGFR, c-Met, Src, and downstream PI3K/AKT/mTOR pathways [7,11,38]. Additional approaches include the inhibition of ErbB, JNK, FAK, PI3K/PAK, and mTORC1/2, as well as the use of multitarget agents and nanotherapeutics, all of which have shown the ability to suppress tumor growth in experimental models [39,40,41]. Collectively, these findings reinforce the rationale of developing targeted and combinatorial therapies for VSs and underscore the need for further translational and clinical studies.

5. Conclusions

Medical therapy is not intended to replace surgery but rather to complement it as a means of maintaining quality of life and minimizing the iatrogenic harm associated with invasive treatments. Based on the available literature, there is still no formal consensus regarding the optimal dosage, treatment schedule, or duration of therapy. Additionally, the rarity of NF2 renders randomized clinical trials difficult.
Ultimately, clinical trial endpoints should not be limited to tumor volume reduction, as the true goal of treatment is the preservation of neural function and psychological well-being. Patient management should integrate objective measures (MRI/audiometry) with patient-reported outcomes, since reductions in tinnitus-related distress and improvements in quality of life often justify continuing therapy even in the absence of tumor shrinkage.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cimb48030292/s1.

Author Contributions

Conceptualization, D.M. and S.P.; methodology, A.E.A.; software, A.E.A.; validation, C.M., M.S. and M.G.; formal analysis, C.M.; investigation, M.S.; resources, R.N. and L.S.; data curation, A.E.A.; writing—original draft preparation, A.E.A.; writing—review and editing, D.M., S.P. and R.N.; visualization, S.P.; supervision, D.M. and S.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments

During the preparation of this manuscript, the authors used artificial intelligence–based tools solely for language editing, grammatical revision, and to support the synthesis and consistency of information derived from the reviewed literature. The authors critically reviewed and edited all AI-assisted content and took full responsibility for the accuracy, originality, and integrity of the final manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Ahmad, Z.K.; Brown, C.M.; Cueva, R.A.; Ryan, A.F.; Doherty, J.K. ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas. Otol. Neurotol. 2011, 32, 841–847. [Google Scholar] [CrossRef] [Scilit]
  2. Yang, J.; Jia, H.; Li, G.; Huang, M.; Zhu, W.; Wang, Z.; Li, Y.; Wu, H. Intratympanic Gentamicin for Small Vestibular Schwannomas with Intractable Vertigo. Otol. Neurotol. 2018, 39, e699–e703. [Google Scholar] [CrossRef] [Scilit]
  3. Zhao, F.; Li, S.W.; Zhang, S.; Li, P.; Zhao, C.; Zhao, X.B.; Wang, C.H.; Zhang, J.; Wang, B.; Liu, P.N. Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J. Neurosurg. 2022, 138, 1680–1687. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Ammoun, S.; Cunliffe, C.H.; Allen, J.C.; Chiriboga, L.; Giancotti, F.G.; Zagzag, D.; Hanemann, C.O.; Karajannis, M.A. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro-Oncology 2010, 12, 834–843. [Google Scholar] [CrossRef] [Scilit]
  5. Mautner, V.F.; Nguyen, R.; Kutta, H.; Fuensterer, C.; Bokemeyer, C.; Hagel, C.; Friedrich, R.E.; Panse, J. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncology 2010, 12, 14. [Google Scholar] [CrossRef] [Scilit]
  6. Plotkin, S.R.; Duda, D.G.; Muzikansky, A.; Allen, J.; Blakeley, J.; Rosser, T.; Campian, J.L.; Clapp, D.W.; Fisher, M.J.; Tonsgard, J.; et al. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients with Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J. Clin. Oncol. 2019, 37, 3446–3454, Erratum in J. Clin. Oncol. 2020, 38, 656. https://doi.org/10.1200/JCO.20.00058. Erratum in J. Clin. Oncol. 2020, 38, 656. https://doi.org/10.1200/JCO.20.00060. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  7. Sabha, N.; Au, K.; Agnihotri, S.; Singh, S.; Mangat, R.; Guha, A.; Zadeh, G. Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. PLoS ONE 2012, 7, e39412. [Google Scholar] [CrossRef] [Scilit]
  8. Fuse, M.A.; Plati, S.K.; Burns, S.S.; Dinh, C.T.; Bracho, O.; Yan, D.; Mittal, R.; Shen, R.; Soulakova, J.N.; Copik, A.J.; et al. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol. Cancer Ther. 2017, 16, 2387–2398. [Google Scholar] [CrossRef] [Scilit]
  9. Karajannis, M.A.; Legault, G.; Hagiwara, M.; Ballas, M.S.; Brown, K.; Nusbaum, A.O.; Hochman, T.; Goldberg, J.D.; Koch, K.M.; Golfinos, J.G.; et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology 2012, 14, 1163–1170. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  10. Garcia, M.R.; Hagiwara, M.; Yaffe, A.; Mitchell, C.; Akshintala, S.; Nicolaides, T.; Phadnis, S.S.; Yohay, K.; Feng, Y.; Goldberg, J.D.; et al. Phase II study of axitinib in patients with NF2-related schwannomatosis and progressive vestibular schwannomas. Neurooncol. Adv. 2025, 7, vdaf083. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  11. Petrilli, A.M.; Garcia, J.; Bott, M.; Klingeman Plati, S.; Dinh, C.T.; Bracho, O.R.; Yan, D.; Zou, B.; Mittal, R.; Telischi, F.F.; et al. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. Oncotarget 2017, 8, 31666–31681. [Google Scholar] [CrossRef] [Scilit]
  12. Vlashi, R.; Sun, F.; Zheng, C.; Zhang, X.; Liu, J.; Chen, G. The molecular biology of NF2/Merlin on tumorigenesis and development. FASEB J. 2024, 38, e23809. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef] [Scilit]
  14. Gugel, I.; Zipfel, J.; Hartjen, P.; Kluwe, L.; Tatagiba, M.; Mautner, V.F.; Schuhmann, M.U. Managing NF2-associated vestibular schwannomas in children and young adults: Review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality. Childs Nerv. Syst. 2020, 36, 2471–2480. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  15. Hawasli, A.H.; Rubin, J.B.; Tran, D.D.; Adkins, D.R.; Waheed, S.; Hullar, T.E.; Gutmann, D.H.; Evans, J.; Leonard, J.R.; Zipfel, G.J.; et al. Antiangiogenic agents for nonmalignant brain tumors. J. Neurol. Surg. Part B Skull Base 2013, 74, 136–141. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  16. Goutagny, S.; Raymond, E.; Esposito-Farese, M.; Trunet, S.; Mawrin, C.; Bernardeschi, D.; Larroque, B.; Sterkers, O.; Giovannini, M.; Kalamarides, M. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J. Neurooncol. 2015, 122, 313–320. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Plotkin, S.R.; Allen, J.; Dhall, G.; Campian, J.L.; Clapp, D.W.; Fisher, M.J.; Jain, R.K.; Tonsgard, J.; Ullrich, N.J.; Thomas, C.; et al. Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro-Oncology 2023, 25, 1498–1506. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  18. Karajannis, M.A.; Legault, G.; Hagiwara, M.; Giancotti, F.G.; Filatov, A.; Derman, A.; Hochman, T.; Goldberg, J.D.; Vega, E.; Wisoff, J.H.; et al. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology 2014, 16, 292–297. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  19. Nghiemphu, P.L.; Vitte, J.; Dombi, E.; Nguyen, T.; Wagle, N.; Ishiyama, A.; Sepahdari, A.R.; Cachia, D.; Widemann, B.C.; Brackmann, D.E.; et al. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. J. Neurooncol. 2024, 167, 339–348. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  20. Douwes, J.P.J.; Hensen, E.F.; Jansen, J.C.; Gelderblom, H.; Schopman, J.E. Bevacizumab Treatment for Patients with NF2-Related Schwannomatosis: A Single Center Experience. Cancers 2024, 16, 1479. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  21. Webb, M.J.; Neth, B.J.; Webb, L.M.; Van Gompel, J.J.; Link, M.J.; Neff, B.A.; Carlson, M.L.; Driscoll, C.L.; Dornhoffer, J.; Ruff, M.W.; et al. Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients. Neurooncol. Adv. 2023, 5, vdad123. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  22. Killeen, D.E.; Klesse, L.; Tolisano, A.M.; Hunter, J.B.; Kutz, J.W., Jr. Long-Term Effects of Bevacizumab on Vestibular Schwannoma Volume in Neurofibromatosis Type 2 Patients. J. Neurol. Surg. Part B Skull Base 2019, 80, 540–546. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  23. Fujii, M.; Ichikawa, M.; Iwatate, K.; Bakhit, M.; Yamada, M.; Kuromi, Y.; Sato, T.; Sakuma, J.; Saito, K. Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients. Neurol. Med. Chir. 2020, 60, 75–82. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  24. Marinelli, J.P.; Lees, K.A.; Tombers, N.M.; Lohse, C.M.; Carlson, M.L. Impact of Aspirin and Other NSAID Use on Volumetric and Linear Growth in Vestibular Schwannoma. Otolaryngol. Head. Neck Surg. 2019, 160, 1081–1086. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Renzi, S.; Michaeli, O.; Salvador, H.; Alderete, D.; Ponce, N.F.; Zapotocky, M.; Hansford, J.R.; Malalasekera, V.S.; Toledano, H.; Maguire, B.; et al. Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. Pediatr. Blood Cancer 2020, 67, e28228. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Alanin, M.C.; Klausen, C.; Caye-Thomasen, P.; Thomsen, C.; Fugleholm, K.; Poulsgaard, L.; Lassen, U.; Mau-Sorensen, M.; Hofland, K.F. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur. Arch. Otorhinolaryngol. 2015, 272, 3627–3633. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Hochart, A.; Gaillard, V.; Baroncini, M.; André, N.; Vannier, J.P.; Vinchon, M.; Dubrulle, F.; Lejeune, J.P.; Vincent, C.; Nève, V.; et al. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J. Neurooncol. 2015, 124, 229–236. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Blakeley, J.O.; Ye, X.; Duda, D.G.; Halpin, C.F.; Bergner, A.L.; Muzikansky, A.; Merker, V.L.; Gerstner, E.R.; Fayad, L.M.; Ahlawat, S.; et al. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J. Clin. Oncol. 2016, 34, 1669–1675, Erratum in J. Clin. Oncol. 2026, JCO2600231. https://doi.org/10.1200/JCO-26-00231. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Plotkin, S.R.; Halpin, C.; McKenna, M.J.; Loeffler, J.S.; Batchelor, T.T.; Barker, F.G., 2nd. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol. Neurotol. 2010, 31, 1135–1143. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  30. Morris, K.A.; Golding, J.F.; Axon, P.R.; Afridi, S.; Blesing, C.; Ferner, R.E.; Halliday, D.; Jena, R.; Pretorius, P.M.; The UK NF2 Research Group; et al. Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: A nationally coordinated approach to delivery and prospective evaluation. Neurooncol. Pract. 2016, 3, 281–289. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  31. Comes, P.C.; Peyre, M.; Sanson, M.; Sterkers, O.; Bernardeschi, D.; Kalamarides, M. Current Management of Large Vestibular Schwannomas for NF2 Patients in a National Reference Center. Laryngoscope 2021, 131, E98–E107. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Plotkin, S.R.; Ardern-Holmes, S.L.; Barker, F.G., 2nd; Blakeley, J.O.; Evans, D.G.; Ferner, R.E.; Hadlock, T.A.; Halpin, C.; REiNS International Collaboration. Hearing and facial function outcomes for neurofibromatosis 2 clinical trials. Neurology 2013, 81, S25–S32. [Google Scholar] [CrossRef] [Scilit]
  33. Trotti, A.; Colevas, A.D.; Setser, A.; Rusch, V.; Jaques, D.; Budach, V.; Langer, C.; Murphy, B.; Cumberlin, R.; Coleman, C.N.; et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 2003, 13, 176–181. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Plotkin, S.R.; Merker, V.L.; Halpin, C.; Jennings, D.; McKenna, M.J.; Harris, G.J.; Barker, F.G. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: A retrospective review of 31 patients. Otol. Neurotol. 2012, 33, 1046–1052. [Google Scholar] [CrossRef] [Scilit]
  35. Gugel, I.; Kluwe, L.; Zipfel, J.; Teuber, C.; Tatagiba, M.; Mautner, V.F.; Schuhmann, M.U.; Grimm, F. Minimal Effect of Bevacizumab Treatment on Residual Vestibular Schwannomas after Partial Resection in Young Neurofibromatosis Type 2 Patients. Cancers 2019, 11, 1862. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  36. Friedman, H.S.; Prados, M.D.; Wen, P.Y.; Mikkelsen, T.; Schiff, D.; Abrey, L.E.; Yung, W.K.; Paleologos, N.; Nicholas, M.K.; Jensen, R.; et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27, 4733–4740. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Lu, V.M.; Ravindran, K.; Graffeo, C.S.; Perry, A.; Van Gompel, J.J.; Daniels, D.J.; Link, M.J. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: A systematic review and meta-analysis of treatment outcomes. J. Neurooncol. 2019, 144, 239–248. [Google Scholar] [CrossRef] [Scilit]
  38. González-Rodriguez, M.A.; Troutman, S.; Bayle, S.; Lester, D.K.; Grove, M.; Duckett, D.; Kareta, M.S.; Kissil, J.L. Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis. Oncogene 2024, 43, 2995–3002. [Google Scholar] [CrossRef] [Scilit]
  39. Dilwali, S.; Briët, M.C.; Kao, S.Y.; Fujita, T.; Landegger, L.D.; Platt, M.P.; Stankovic, K.M. Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth. Mol. Oncol. 2015, 9, 1359–1370. [Google Scholar] [CrossRef] [Scilit]
  40. Huegel, J.; Dinh, C.T.; Martinelli, M.; Bracho, O.; Rosario, R.; Hardin, H.; Estivill, M.; Griswold, A.; Gultekin, S.; Liu, X.-Z.; et al. CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells. Oncotarget 2022, 13, 890–904. [Google Scholar] [CrossRef] [Scilit]
  41. Sagers, J.E.; Beauchamp, R.L.; Zhang, Y.; Vasilijic, S.; Wu, L.; DeSouza, P.; Seist, R.; Zhou, W.; Xu, L.; Ramesh, V.; et al. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma. Sci. Rep. 2020, 10, 4211. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.